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Abstract
Background Previously, we reported on our single centre
results regarding the diagnostic yield of stereotactic needle
biopsies of brain lesions. The yield then (1996–2006) was
89.4%. In the present study, we review and evaluate our
experience with intraoperative frozen-section histopatho-
logic diagnosis on-demand in order to improve the
diagnostic yield.
Methods One hundred sixty-four consecutive frameless
biopsy procedures in 160 patients (group 1, 2006–2010)
were compared with the historic control group (group 2, n=
164 frameless biopsy procedures). Diagnostic yield, as well
as demographics, morbidity and mortality, was compared.
Statistical analysis was performed by Student's t, Mann–
Whitney U, Chi-square test and backward logistic regres-
sion when appropriate.
Results Demographics were comparable. In group 1, a non-
diagnostic tissue specimen was obtained in 1.8%, compared
to 11.0% in group 2 (p=0.001). Also, both the operating
time and the number of biopsies needed were decreased
significantly. Procedure-related mortality decreased from
3.7% to 0.6% (p=0.121). Multivariate analysis only proved
operating time (odds ratio (OR), 1.012; 95% confidence
interval (CI), 1.000–1.025; p=0.043), a right-sided lesion
(OR, 3.183; 95% CI, 1.217–8.322; p=0.018) and on-
demand intraoperative histology (OR, 0.175; 95% CI,
0.050–0.618; p=0.007) important factors predicting non-
diagnostic biopsies.
Conclusions The importance of a reliable pathological
diagnosis as obtained by biopsy must not be under-
estimated. We believe that when performing stereotactic
biopsy for intracranial lesions, next to minimising morbid-
ity, one should strive for as high a positive yield as
possible. In the present single centre retrospective series,
we have shown that using a standardised procedure and
careful on-demand intraoperative frozen-section analysis
can improve the diagnostic yield of stereotactic brain
biopsy procedures as compared to a historical series.
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Introduction
In an earlier report, we demonstrated our single centre results
with both frame-based and frameless neuronavigational
image-guided techniques in the context of needle biopsies of
brain lesions [7]. We reported no differences in diagnostic
yield, complications and biopsy-related mortality between
both techniques, as corroborated by others [36, 40, 41].
On the matter of diagnostic yield, we discussed the
possible importance of intraoperative frozen-section or
cytological smear preparations. Our previous results, when
no intraoperative histological diagnosis was readily avail-
able, showed an overall diagnostic yield of 89.4%, which is
on the lower spectrum of yield reported by others [1, 9, 11,
12, 17, 19, 34, 36, 40]. We believe that neurosurgeons
should strive for as high a diagnostic yield as possible,
respecting the possible morbidity or even mortality,
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although small, the patient confronts when undergoing an
intracranial biopsy procedure. Since several authors have
shown the benefit of intraoperative histopathologic diagno-
sis and/or the use of modern intraoperative imaging
techniques, improving the diagnostic yield up to as high
as 99.2% [4, 14, 20, 22, 31, 32], we implemented
intraoperative histopathologic diagnosis into our stand-
ardised biopsy procedure in order to possibly improve on
our results.
In the present study, we reviewed and evaluated our
experience with the use of intraoperative frozen-section
diagnosis on-demand, when the neurosurgeon performing
the biopsy on macroscopic observation was hesitant about
the pathologic nature of the tissue sample.
Patients and methods
We reviewed a consecutive series of patients who had
undergone an image-guided stereotactic intracranial biopsy
procedure at the Erasmus MC from November 2006 until
January 2010. This series of patients succeeded the series of
465 uninterrupted cerebral biopsies, of which 164 were
frameless biopsy procedures, published in our earlier report
[7]. The data were prospectively gathered, but reviewed in a
retrospective manner. One hundred sixty-four frameless
biopsy procedures were performed in 160 patients.
Patient and pre-operative neuroimaging characteristics
Age, gender, post-operative biopsy-related complications
(morbidity) and mortality, duration of hospital stay as well
as operating time, biopsy method used, number of biopsies
and complications were extracted from case notes and
operative reports. The site of the targeted lesion was
obtained from pre-operative computed tomographic or
magnetic resonance (MR) imaging. The eventual diagnosis
was obtained from the pathological report, from which the
diagnostic yield was determined.
Operative technique
The techniques of frameless image-guided stereotactic biop-
sies applied in our centre have been described previously [7].
One hundred sixty-four biopsies were performed using the
frameless stereotaxy protocol under general anaesthesia and
head-fixation in a three-point Mayfield clamp. Intraoperative
image guidance and the surgical plan were obtained using
the Stealth Treon™ system (Medtronic Inc., Minneapolis,
MN, USA). Tissue samples approximately 8-mm-long and
1-mm-thick were thus obtained.
In general, four biopsies were obtained at the pre-
operatively suggested target, as well as two to four more
biopsies at a site proximal to the target on the same biopsy
trajectory. The macroscopic aspect of the biopsy was assessed,
and it was considered pathological when one or more of the
following was observed: (1) glazy/oedematous aspect, (2)
haemorrhagic component and (3) dark-greyish aspect. A brain
tissue sample was regarded normal when clearly white matter
was observed. Intraoperative freeze sectioning was per-
formed, only then when the surgeon was uncertain about the
pathologic nature of the tissue sample, i.e. the macroscopic
appearance of the acquired tissue resembled normal brain. If
diagnostic tissue was not obtained, all parameters and
measurements were rechecked to ensure accurate localisation,
after which, a repeat biopsy sample could then be sent, via the
same or a new trajectory, if need be.
Statistical analysis
Statistical analysis was performed with SPSS 15.0 for
Windows (SPSS Inc., Chicago, IL, USA). The present 164
biopsies, with the abovementioned standardised procedure
and intraoperative histopathologic diagnosis on-demand
(group 1), were compared to the historic control of 164
frameless biopsies that were reported previously and did
not include intraoperative diagnosis (group 2). Continuous
data were compared using the Student's t test for parametric
data. For non-parametric data, the Mann–Whitney U test
was used. These are presented as mean values±standard
deviations, unless otherwise specified. Proportions were
compared with Chi-square and Fisher's exact test and
presented as percentages. p values <0.05 were considered
statistically significant. In order to analyse factors relating
to the risk of a non-diagnostic biopsy, the variables selected
were dichotomised and initially explored univariately as
described above. Variables for which there was not a high
probability of association (p>0.10) were excluded from the
final regression model. Backward stepwise logistic regres-
sion was used for this purpose, and odds ratios (OR) and
95% confidence intervals (CI) are presented.
Results
In Table 1, patient and peri-operative characteristics of
stereotactic biopsies in patients of group 1 and 2 are shown.
There were no differences in age and gender distribution. The
peri-operative complication rate was also similar. Interesting-
ly, the number of biopsies taken and the overall operating time
both decreased significantly (p<0.001 and p<0.001, respec-
tively) when comparing with the historical group 2.
The location of the lesion intended for biopsy was not
significantly different when compared to side and anatom-
ical site. Left- and right-sided lesions were equally divided
(group 1 vs. group 2, 39.0% and 36.0% vs. 39.6% and
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40.9%, respectively). In patients of group 1, the three most
often biopsied tumours were frontal (22.5%), parietal
(22.0%) and thalamic (14.0%) lesions.
Post-operative complications occurred in 14 (8.5%) and
19 (11.6%) of operations in groups 1 and 2, respectively. Of
these, four symptomatic haemorrhages in each group
(2.4%) were diagnosed by post-operative computed tomog-
raphy. There was no statistically significant difference
between groups 1 and 2 in the frequency of occurrence of
post-operative complications. In the most recent patients
(group 1), there was one death (0.6%) attributable to the
surgical procedure, i.e. death occurring within 30 days as a
result of symptomatic post-operative haemorrhage or
oedema. There were six biopsy-related deaths (3.7%) in
group 2, which did not reach statistical significance (p=
0.121, Fisher's exact).
Diagnostic yield
The overall diagnostic yield of group 1 was 98.2%, i.e. a
histological diagnosis was established in 161 of 164 biopsy
procedures, whereas in three (1.8%), the biopsy was non-
diagnostic. In one patient, this resulted in a repeated biopsy
procedure that resulted in the diagnosis of a lymphoma. The
second and third patient underwent a subsequent cranioto-
my when a glioblastoma and metastasis of lung carcinoma
was diagnosed, respectively. In 15 cases (8.9%), the
surgeon judged the tissue obtained to resemble normal
brain and therefore requested for an intraoperative frozen-
section diagnosis by the neuropathologist. When non-
diagnostic, this prompted for another tissue sample in the
chosen trajectory. In the period from August 1996 until
October 2006, i.e. group 2, when there was no availability
of intraoperative histopathologic diagnosis, the diagnostic
yield was only 89.0%, which is statistically lower compared
with group 1 diagnostic yield (p=0.001). Table 2 shows the
histological diagnoses that were made on the tissue samples
taken in both groups. On average, 7.4 (range, 1–19) and 9.0
(1–24) tissue samples were taken during the biopsy procedure
in groups 1 and 2, respectively (p<0.001, Table 1).
Table 3 shows the results of the univariate analysis
performed to establish the factors related to obtaining a
non-diagnostic biopsy specimen (n=21). In the subsequent
multivariate regression analysis, only operating time (OR,
1.012; 95% CI, 1.000–1.025; p=0.043), a right-sided lesion
(OR, 3.183; 95% CI, 1.217–8.322; p=0.018) and the use of
on-demand intraoperative histopathologic examination
(OR, 0.175; 95% CI, 0.050–0.618; p=0.007) showed to
be important factors.
Discussion
Previously, we have shown the diagnostic yield of
stereotactic biopsy either by frame-based or frameless
techniques to be equal, as were the morbidity and mortality
related to the procedure [7]. The overall diagnostic yield in
the previous report was 89.4%, which might be regarded
lying on the lower spectrum of the yield obtained by others
[1, 9, 11, 12, 17, 19, 34, 36, 40]. The present study suggests
that by using on-demand frozen-section analysis of tissue
specimens begotten by biopsy, the diagnostic yield can be
dramatically improved (98.2%).
Several other authors have corroborated these results, i.e.
performing intraoperative frozen-section or cytological
smear preparations will increase the rate on a reliable
histopathological diagnosis up to as high as 99.2% [4, 14,
17, 29, 31, 38]. McDermott and Bernstein, in Neuro-
oncology: The Essentials (p. 115), actually state ‘[…] The
management of the failed biopsy begins in the operating
room where intraoperative examination of tissue is manda-
tory to ensure that diagnostic tissue is in fact obtained […]’.
Nevertheless, the five most recent reports, illustrating
diagnostic yields of 99.3% [35], 94% [30], 90.6% [5],
89.8% [1] and 83.6% [37], do not mention intraoperative
pathologic confirmation. Also, in our series, we were not
able to perform intraoperative cytological studies in all
biopsy procedures. This was primarily due to logistic
considerations, such as pressure on the operating theatre
regarding time and the unavailability of adequate neuro-
pathologic support on all biopsies. Therefore, we turned to
on-demand frozen-section analysis, i.e. the surgeon
performing the biopsy assessed the tissue specimen macro-
scopically as normal brain or pathological tissue sample
and, when uncertain, requested the neuropathologist for
intraoperative confirmation. Apparently, concluded from
the results shown in the present study, there is no need for
Table 1 Patient and peri-operative characteristics of groups 1 and 2
Group 1
(n=164)
Group 2
(n=164)
p value
Male (%) 55.5 56.7
Age (years±SD) 52.6±18.4 55.0±17.2
Operating time
(min±SD)
108.5±34.2 127.1±32.8 <0.001
Number of
biopsies±SD
7.4±3.3 9.0±3.8 <0.001
Complication (%)
Haemorrhage 3.0 3.0
Technical failure 2.4 3.7
Shown are percentages and mean values±standard deviations (SD).
Group 1: period November 2006 until April 2009, with intraoperative
histopathological diagnosis on-demand; group 2: period August 1996
until October 2006, without the possibility of intraoperative histo-
pathological diagnosis
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an intraoperative cytological preparation, and therefore, a
neuropathologist standby for every stereotactic cerebral
biopsy procedure when an experienced surgeon evaluates
the tissue samples obtained. These results are corroborated
by the recent article of Shooman et al. who on top of this
state that routine intraoperative neuropathological examina-
tion is not needed at all [35].
Table 4 shows the diagnostic yield, complication rates,
deaths and methods used to ensure a greater diagnostic yield
in the most recent biopsy series. Since 2001, a total of 12,038
biopsy procedures are collected in the literature, with an
overall diagnostic yield ranging from 83.6% to 100%.
Positron emission tomography imaging, MR perfusion and
MR imaging spectroscopy integrated into the planning for
stereotactic biopsy procedures to determine the trajectory and
selection of the appropriate target promise to be important
adjuncts to improve diagnostic yield and to decrease sampling
error, especially when low-grade gliomas are involved [6, 13,
15, 24, 27, 28, 32, 33]. Recent studies show a yield of 100%,
although patient numbers are relatively small [6, 13, 15, 24,
32, 33]. Additional use of metabolic imaging data acquired
with MR spectroscopy, more specifically, the ratio of N-
acetyl aspartate and choline-containing compounds, for
target selection can potentially increase the diagnostic
efficacy of biopsy procedures.
Another issue to be addressed is the diagnostic accuracy,
i.e. the rate of sampling error as established by subsequent
open craniotomy. In literature, accuracy rates ranging from
73% to 97% have been reported [2, 7, 17, 30, 40]. Chernov
et al. compared the diagnostic efficacy of stereotactic brain
biopsy performed with and without additional use of
spectroscopic imaging and found that spectroscopy was
superior, although not significantly due to the small number
of patients, in reaching a diagnosis at all (100% vs. 90%)
[6]. Diagnostic accuracy, however, could not be improved
by using spectroscopy imaging (67% vs. 79%, MR imaging
with and without spectroscopy, respectively).
In the present study, an important difference with the
historical control was the use of on-demand intraoperative
histological confirmation of pathological tissue, which was
Table 3 Results of univariate analysis to establish confounding factors related to obtaining a non-diagnostic biopsy specimen
Diagnostic (n=305) Non-diagnostic (n=21) p value
Male (%) 55.7 66.6 0.371
Age (years±SD) 53.9±17.7 5.8±18.2 0.828
Tumour side
Right 38.7 66.7 0.019
Left 38.7 19.0 0.101
Tumour location (frontal, parietal, temporal, etc.) 0.388
Surgeon 0.421
Operating time (min±SD) 116.0±33.4 138.1±39.6 0.004
Number of biopsies±SD 8.3±3.7 7.3±2.7 0.259
On-demand intraoperative frozen-section histology 52.8 14.3 0.001
Peri-operative complication 6.3 4.8 1.000
Post-operative complication 10.5 4.8 0.708
Biopsy-related death 2.3 0 1.000
Shown are percentages and mean values±standard deviations (SD)
Table 2 Histological diagnoses made on tissue samples acquired by
stereotactic biopsy
Diagnosis (%) Group 1
(n=164)
Group 2
(n=164)
p value
Non-diagnostic 1.8 11.0 0.001
Malignant glioma 53.0 51.3
Low-grade glioma 12.2 14.6
Lymphoma 14.0 7.9
Metastasis 3.0 7.3
Infection/vasculitis/
MS/abscess
12.2 6.7
Craniopharyngioma
cysts
1.8 1.2
Othersa 1.8 0
Shown are percentages. Group 1: period November 2006 until April
2009, with intraoperative histopathological diagnosis on-demand;
group 2: period August 1996 until October 2006, without the
possibility of intraoperative histopathological diagnosis. Malignant
glioma includes astrocytoma, oligoastrocytoma, oligodendroglioma
WHO grade III and glioblastoma (WHO grade IV). Low-grade glioma
includes astrocytoma, oligoastrocytoma and oligodendroglioma WHO
grade II
MS multiple sclerosis
a Include meningioma, medulloblastoma, teratoma, malignant peripheral
nerve sheath tumour and old haematoma
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confirmed by multivariate analysis to be an important
factor to decrease the chance on a non-diagnostic tissue
specimen. However, due to the retrospective nature of the
present study, some confounding factors should be put
forward that may influence the overall results. As a result of
technological advance and ease of use, the frameless
stereotactic technique has been used more frequently in
recent times at our neurosurgical clinic (97.6% vs. 35.3%,
respectively). Although we, in concordance with others,
have previously shown that this does not influence
diagnostic yield [7, 36, 40, 41], Dorward et al. found
disagreeing results, concluding that frameless techniques
are superior to the gold standard of frame-based biopsy [8].
To exclude this possible confounding factor, we compared
the most recent frameless biopsy series (group 1) with the
historical control of frameless biopsies only. Furthermore,
the effect of an initial learning curve cannot be ruled out.
Another, more important factor might be the number of
surgeons performing the biopsy procedures. These differ
significantly between the historical and the present group of
patients. In group 2, a total of 20 surgeons, whereas in
group 1, only 15 surgeons were involved with the
stereotactic biopsy procedures. In the most recent group
(group 1), two surgeons (RD and JWS) performed 51.8% of
surgeries and supervised another 12.8%. One might argue
that due to a surgeon's increased experience, he/she is apt to
Table 4 Diagnostic yield in recent biopsy series
Author (year) n Yield Method to improve yield Morbidity Mortality
Kaakaji et al. (2001) [16] 269 97.1 None 3.0 0.4
Paleologos et al. (2001) [31] 125 97.6 Intraoperative histology 2.4 0.8
Ulm et al. (2001) [39] 200 98.5 None 2.0 0
Bhardwaj et al. (2002) [3] 76 98.7 None 2.6 0
Dorward et al. (2002) [8] 155 96.8 Intraoperative histology 16.1 3.2
Gralla et al. (2003) [10] 57 98 Intraoperative histology 3.5 0
Kim et al. (2003) [17] 308 91.7 Intraoperative histology 3.9 0.6
Maia et al. (2004) [24] 21 100 MR perfusion NA NA
Pirotte et al. (2004) [32] 32 100 Spectroscopy NA NA
Aker et al. (2005) [2] 130 94 Intraoperative histology 0.8 0
Grossman et al. (2005) [11] 355 93.8 None 3.6 0.6
Hemm et al. (2005) [13] 10 100 Spectroscopy NA NA
Heper et al. (2005) [14] 130 99.2 Intraoperative histology 0.7 0
McGirt et al. (2005) [26] 270 93 None 5.0 1.0
Smith et al. (2005) [36] 213 90 None 4.0 0.4
Tilgner et al. (2005) [38] 5,000 90.3 Intraoperative histology 2.7 0.7
Ferreira et al. (2006) [9] 170 92 None 2.9 1.2
Shastri-Hurst et al. (2006) [34] 207 89.3 Intraoperative histology 6.4 1.9
Woodworth et al. (2006) [41] 270 90 None 4.0 1.0
Pirotte et al. (2007) [33] 20 100 Spectroscopy 10.0 0
Dammers et al. (2008) [7] 465 89.5 None 11.7 3.9
Hermann et al. (2008) [15] 9 100 Spectroscopy NA NA
Kongkham et al. (2008) [18] 622 98.4 Intraoperative histology 6.9 1.3
Lunsford et al. (2008) [23] 1,664 NA None 3.1 0.1
Landriel et al. (2008) [21] 192 90.6 Intraoperative histology 3.6 2.1
Air et al. (2009) [1] 284 89.8 None 6.7 2.0
Chernov et al. (2009) [6] 69 94 Spectroscopy (100%) 1.4 0
Owen and Linskey (2009) [30] 106 94 None 3.8 0
Teixeira et al. (2009) [37] 176 83.6 None 6.4 0.6
Chen et al. (2009) [5] 299 90.6 None 7.4 1.3
Shooman et al. (2010) [35] 134 99.3 None 2.2 1.5
Total 12,038 94.7 (83.6–100) 4.7 (0.7–16.1) 0.9 (0–3.9)
Present series 164 98.2 On-demand intraoperative histology 8.5 0.6
Diagnostic yield, morbidity and mortality are expressed in percentages
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prepare a biopsy trajectory and target that ensures less
chance on complications and a higher chance on a positive
histological diagnosis. For this, there is no evidence in
recent literature as far as we are aware, although Shastri-
Hurst et al. touched upon the subject in the “Results”
section and found no evidence that the individual
performing the biopsy most frequently had better results
in terms of complication rate or non-diagnostic rate [34].
Lastly, the recent 164 cases were all histologically
examined by one experienced dedicated neuropathologist
(JMK), whereas in the past, three pathologists performed
the histopathologic diagnosis. A single dedicated neuropa-
thologist might be able to provide a diagnosis more often.
Furthermore, the changing tumour classification and grad-
ing by the World Health Organisation might aid to construct
a more proficient diagnosis nowadays.
The possible advantages of on-demand intraoperative
frozen-section analysis are its cost-effectiveness concerning
the consultation of a neuropathologist and the need for
repeat surgery. More importantly, a non-diagnostic biopsy
has an imminent effect on a patient's further treatment. On-
demand histopathology, however, demands experienced
and dedicated neuro-oncologic trained neurosurgeons [35].
Nevertheless, the issue of diagnostic accuracy, i.e. biopsy
sampling error, remains unresolved. As described above,
newly available diagnostic techniques might add to locate
the adequate biopsy site and decrease sampling error.
Although tumour verification might be warranted, the
treating physician should always also consider the
morbidity and mortality related to the biopsy procedure.
Of the 12,038 procedures in recent literature (Table 4),
the average procedure-related morbidity was 4.7% (range,
0.7–16.1%), compared to our own recent series (8.5%).
These vary from minor complications to devastating
neurological sequelae that can influence a patients'
independence. The average mortality rate was 0.9%
(range, 0–3.9%) and 0.6% in recent literature and the
present series, respectively, from which one might con-
clude that a brain biopsy is a safe procedure.
Concluding, the importance of a reliable pathological
diagnosis as obtained by biopsy, notwithstanding the
possibility of sampling error [25, 28], must not be under-
estimated. Both with regard to the possible risks for the
patients, such as (increase of) neurological deficits by
oedema or haemorrhage and even death, as well as with
regard to the further treatment that might be warranted for
each individual patient. In the present single centre
retrospective series, we have shown that using a stand-
ardised procedure and careful on-demand intraoperative
frozen-section analysis, when the macroscopic aspects is
not clearly pathological, can improve the diagnostic yield of
stereotactic brain biopsy procedures as compared to a
historical series.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
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Comment
The colleagues of Rotterdam compared the diagnostic yield of
frameless stereotactic biopsies with or without the possibility of
frozen section and smear preparation assessment during biopsy. The
option of asking a neuropathologist to the OR clearly decreased non-
diagnostic samples in the final neuropathological evaluation: 1.8% (3
of 164 frameless biopsies 2006-2010) vs. 11% (18 of 160 frameless
biopsies 1996-2006). The average numbers of samples were 7.4 vs.
9.0 per patient. Neurosurgeons assessed the macroscopic appearance
of the samples as pathologic (oedematous, hemorrhagic, or dark-
grayish) - or as normal brain, the only indication for the intra-
operative freezesectioning.
The risk of 11% of repeat biopsy and delayed therapy would
require reduction – but how?
1. Instant and routine microscopic verification of the presence of
representative samples with a putative first diagnosis in the OR – in
real life? Neurosurgical units are served by a few neuropathologists at
best – often by one or two. Are they willing to walk from their
microscopy desks with piles of slide trays to the OR in the other end
of the building or in the next one? Few units really have a
neuropathologist sitting in the OR until the verification is done.
2. On-demand microscopic assessment in the OR of dubious
samples only – as cleverly arranged above.
3. Transfer of fresh samples to the neuropathology unit – and
waiting for tens of minutes a phone call from a neuropathologist.
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